KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.

Xinyan Yang, Lihong Wang, Kewu Huang, Wei Tang, Eli John Berame, Hae-Sim Park, Gillian Hunter, Wei Jiang, Chengyi Chloe Wu, Chiju Wendy Min, Katarzyna Domek-Zielinska, Harbans Lal, Nestor A Molfino, Sandhia S Ponnarambil, Nanshan Zhong

J Allergy Clin Immunol Pract 13(11) 3011-3020.e9

PMID40782846
PMCID-
DOI10.1016/j.jaip.2025.07.046
发表日期2025-08-09
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Tezepelumab, a human monoclonal antibody that blocks thymic stromal lymphopoietin, reduced the annualized asthma exacerbation rate (AAER) and improved lung function, asthma control, and health-related quality of life (HRQoL) in patients with severe, uncontrolled asthma (SUA) in the global, phase 3 NAVIGATOR study (NCT03347279). OBJECTIVE: DIRECTION was a phase 3, multicenter, double-blind study that assessed the efficacy and safety of tezepelumab in adults with SUA in China, the Philippines, and the Republic of Korea. METHODS: Patients (18-80 years old) with SUA (no baseline biomarker restrictions) were randomized 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end point was the AAER over 52 weeks. Key secondary end points were changes from baseline to week 52 in prebronchodilator forced expiratory volume in 1 second (FEV1) and Asthma Control Questionnaire-6 (ACQ-6), Asthma Quality of Life Questionnaire (standardized) for patients 12 years and older (AQLQ[S]+12), and Asthma Symptom Diary (ASD) scores. Safety was also assessed. RESULTS: Overall, 400 patients received tezepelumab (n = 201) or placebo (n = 199). Tezepelumab significantly reduced AAERs versus placebo by 74% (95% confidence interval [CI]: 61, 83; P < .001) in the overall population and by 60% (95% CI: 31, 77) in patients with baseline blood eosinophil count <300 cells/μL. Tezepelumab significantly improved prebronchodilator FEV1 (least-squares mean difference: 0.24 L [95% CI: 0.16, 0.32]) and ACQ-6, AQLQ(S)+12, and ASD scores at week 52 versus placebo (all P ≤ .001). No new safety concerns were identified. CONCLUSIONS: Tezepelumab reduced exacerbations and improved lung function, asthma control, and HRQoL in Asian patients with SUA, consistent with prior study findings.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。